Literature DB >> 29904105

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma.

Viktor Grünwald1, Berit Eberhardt2,3, Axel Bex4, Anne Flörcken5, Thomas Gauler6, Thorsten Derlin7, Martin Panzica8, Hans Roland Dürr9, Knut Achim Grötz10, Rachel H Giles3,11, Christian von Falck12, Anno Graser13, Alexander Muacevic14, Michael Staehler15.   

Abstract

Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated bone metastases can be curable in select patients. Current data support a multimodal management strategy that includes wide resection of lesions, radiotherapy, systemic therapy, and other local treatment options, which can improve quality of life and survival. Nevertheless, the optimal approach for metastatic bone disease in RCC has not yet been defined and practical recommendations are rare. To improve the management and outcomes of patients with RCC and bone metastases, the International Kidney Cancer Coalition and the interdisciplinary working group on renal tumours of the German Cancer Society convened a meeting of experts with a global perspective to perform an unstructured review and elaborate on current treatment strategies on the basis of published data and expertise. The panel formulated recommendations for the diagnosis and treatment of patients with RCC and metastasis to the bone. Furthermore, the experts summarized current challenges and unmet patient needs that should be addressed in the future.

Entities:  

Mesh:

Year:  2018        PMID: 29904105     DOI: 10.1038/s41585-018-0034-9

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  14 in total

1.  A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.

Authors:  Kunal Desai; Landon Brown; Wei Wei; Matthew Tucker; Chester Kao; Emily Kinsey; Brian Rini; Kathryn Beckermann; Tian Zhang; Moshe C Ornstein
Journal:  Target Oncol       Date:  2021-08-11       Impact factor: 4.493

2.  Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study.

Authors:  Cem Onal; Ozan Cem Guler; Pervin Hurmuz; Guler Yavas; Burak Tilki; Ezgi Oymak; Cagdas Yavas; Gokhan Ozyigit
Journal:  Strahlenther Onkol       Date:  2022-06-13       Impact factor: 4.033

Review 3.  Imaging considerations for thermal and radiotherapy ablation of primary and metastatic renal cell carcinoma.

Authors:  Mohammad Haroon; Paul Sathiadoss; Rebecca M Hibbert; Satheesh Krishna Jeyaraj; Christopher Lim; Nicola Schieda
Journal:  Abdom Radiol (NY)       Date:  2021-07-10

4.  Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study.

Authors:  Keyi Wang; Zonglin Wu; Guangchun Wang; Heng Shi; Jinbo Xie; Lei Yin; Tianyuan Xu; Weipu Mao; Bo Peng
Journal:  Int Braz J Urol       Date:  2021 Mar-Apr       Impact factor: 1.541

5.  Androgen receptor decreases renal cell carcinoma bone metastases via suppressing the osteolytic formation through altering a novel circEXOC7 regulatory axis.

Authors:  Dongkui Gong; Yin Sun; Changcheng Guo; Tzong-Jen Sheu; Wei Zhai; Junhua Zheng; Chawnshang Chang
Journal:  Clin Transl Med       Date:  2021-03

6.  MTDH promotes metastasis of clear cell renal cell carcinoma by activating SND1-mediated ERK signaling and epithelial-mesenchymal transition.

Authors:  Anbang He; Shiming He; Cong Huang; Zhicong Chen; Yucai Wu; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  Aging (Albany NY)       Date:  2020-01-24       Impact factor: 5.682

7.  Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?

Authors:  Emily C L Wong; Anil Kapoor
Journal:  Transl Oncol       Date:  2019-12-21       Impact factor: 4.243

8.  Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis.

Authors:  Minyong Kang; Joongwon Choi; Jungyu Kim; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Soo Jeon; Hyun Moo Lee; Se Hoon Park; Cheryn Song; Seong Il Seo
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

9.  Bone Metastasis in Renal Cell Carcinoma Patients: Risk and Prognostic Factors and Nomograms.

Authors:  Zhiyi Fan; Zhangheng Huang; Xiaohui Huang
Journal:  J Oncol       Date:  2021-05-12       Impact factor: 4.375

10.  Metastatic Lesion of the Tibia from Renal Cell Carcinoma.

Authors:  Piotr Młodożeniec; Krzysztof Balawender; Mateusz Zasadny
Journal:  Case Rep Oncol Med       Date:  2021-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.